Retraction: Aromatase Inhibitor-mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer

Overview

Journal Mol Cancer Ther

Date 2018 Nov 4

PMID 30389813

Citations 1

Authors

Raju Khatri

Preeti Shah

Rupa Guha

Feyruz V Rassool

Alan E Tomkinson

Angela Brodie

Anil K Jaiswal

Affiliations

Soon will be listed here.

Citing Articles

Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence.

Wang Y, Jing F, Wang H Adv Ther. 2022; 39(2):862-891.

PMID: 34989983 DOI: 10.1007/s12325-021-01924-2.

References

Khatri R, Shah P, Guha R, Rassool F, Tomkinson A, Brodie A . Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer. Mol Cancer Ther. 2015; 14(7):1728-37. PMC: 4497835. DOI: 10.1158/1535-7163.MCT-14-0672. View